The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB),
including but not limited to those available through the PAAB Forum, the PAAB website, and any PAAB
correspondences, are specifically intended to assist individuals navigating the PAAB preclearance system.
Repurposing or reproducing this content without written consent from the PAAB Commissioner is strictly
prohibited. This prohibition includes, but is not limited to, use in machine learning or AI models.
🎉PAAB Celebrates AstraZeneca’s Industry-Leading Commitment to Innovation
-
Good Morning @Manufacturer @Agency
PAAB is thrilled to announce that AstraZeneca is the first manufacturer to opt into supporting augmentation of the PAAB AI Preclearance Model through use of their de-identified submissions.
We look forward to seeing which manufacturers will join AstraZeneca in seizing this opportunity. Those who opt in before we begin training the first real-life model will be among the first to benefit from this groundbreaking innovation. Don’t miss your chance to be part of this industry-first initiative! Learn more HERE.
